Drugs / Vitamin K2
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01923012 | Sep 2013 → Sep 2014 | atherosclerosis, carotid artery disorder | Azienda Ospedaliera Sant'Anna | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05417880 | Aug 2022 → Feb 2023 | type 2 diabetes mellitus | Scotmann Pharmaceuticals | Unknown | No outcome recorded |
| Phase not applicable1 trial · 1 met primary | ||||||
| — | NCT05547750 | Oct 2022 → Dec 2023 | — | The Third People's Hospital of Chengdu | Completed | Met primary |
| Comparator or background therapy6 trials | ||||||
| Phase 2/3 | NCT04477811 Comparator | Jul → Nov 2020 | end stage renal failure | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT04145492 Comparator | Sep 2019 → Jan 2020 | end stage renal failure | Ain Shams University | Unknown | No outcome recorded |
| Phase 4 | NCT05942053 Comparator | Jul 2023 → Jul 2026 overdue | chronic kidney disease | Tanta University | Recruiting | No outcome recorded |
| Phase 4 | NCT04539418 Comparator | Dec 2016 → Mar 2017 | kidney disorder | Catholic University of Salta | Completed | No outcome recorded |
| Phase 4 | NCT01101698 Comparator | Jun 2009 → Dec 2010 | chronic kidney disease, coronary artery disorder | Medical University of Lodz | Unknown | No outcome recorded |
| — | NCT07206537 Comparator | Apr 2025 → Apr 2026 overdue | — | Ain Shams University | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-04-27 | Laboratorios Rubió | Results OTC Supplements: 2025’s Revolution in Preventive Health laboratoriosrubio.com ↗
A 3-year study in Osteoporosis International found that women taking vitamin K2 (MK-7 form) had significantly reduced age-related bone mineral density decline compared to placebo. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-04-27 | Laboratorios Rubió | OTC Supplements: 2025’s Revolution in Preventive Health laboratoriosrubio.com ↗ |
| 2023-06-29 | NPO Petrovax | The New Product Omegika® in Russian Pharmacies – A Crystal-Clear Omega-3 Concentrate in Combination with Vitamin K2 petrovax.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vitamin K2 | “Empagliflozin 10 mg oral tablets + Vitamin D3 ( 2000 IU ) + Vitamin K2 ( 100 mcg) Once Daily for 3-6 months” NCT05417880 ↗9“vitamin K2 supplementation may serve as a multifaceted intervention” NCT07206537 ↗ |
| Known as | Menaquinone | “supplementation with vitamin K2 at a dose of 90 μg (menaquinone, MK-7) together with 10 μg of cholecalciferol (K+D group) or 10 μg of cholecalciferol (group D)” PMID 26176325 ↗ Jul 20151“Vitamin K2 (Menaquinone)” NCT01923012 ↗ |
| Known as | menaquinone 7 | “Patients orally took capsules containing either vitamin K2 (menaquinone 7), 180 μg, or a similar-looking placebo every day for 8 weeks.” PMID 39466236 ↗ Dec 2024 |
| Known as | Menaquinone-4 | “Randomized placebo-controlled study with vitamine K2 (Menaquinone-4) in calcified carotid stenosis.” NCT01923012 ↗ |
| Known as | MK-7 | “supplementation with vitamin K2 at a dose of 90 μg (menaquinone, MK-7) together with 10 μg of cholecalciferol (K+D group) or 10 μg of cholecalciferol (group D)” PMID 26176325 ↗ Jul 20151“15 patients will take 90 ug of vitamin K2 (MK-7) daily in addition to the standard therapy for 4 months.” NCT04145492 ↗ |
| Action | Activate | “MGP is excretion protein whose mechanism of action is not yet fully explained and which to be activated requires phosphorylation and carboxylation where cofactor is vitamin K” NCT01101698 ↗ |
| Route | Oral | “vitamin k2 (menaquinone) will be given 90 ug per day orally” NCT04477811 ↗ |
| Target | MGP | “The vasculoprotective properties of vitamin K are in part based on the ability to improve gamma-glutamylcarboxylation of MGP, which is a prerequisite for MGP as a calcification...” PMID 25744701 ↗ Feb 2015 |